Comparative Pharmacology
Head-to-head clinical analysis: DICLOFENAC POTASSIUM versus VIVLODEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICLOFENAC POTASSIUM versus VIVLODEX.
DICLOFENAC POTASSIUM vs VIVLODEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates pain, inflammation, and fever.
COX-2 inhibitor; reduces prostaglandin synthesis via inhibition of cyclooxygenase-2 (COX-2) with minimal COX-1 inhibition.
50 mg orally twice daily or 75 mg orally once daily; maximum 150 mg/day. Alternatively, 75 mg intramuscularly once daily (short-term).
Once daily oral administration of 100 mg or 200 mg capsules. The recommended dose is 100 mg once daily; dose may be increased to 200 mg once daily if response is inadequate. Maximum daily dose: 200 mg.
None Documented
None Documented
Terminal elimination half-life is ~1.1 hours (range 0.9–1.6 h). Short half-life supports frequent dosing (e.g., every 6–8 hours) for sustained analgesia.
Terminal elimination half-life of the active moiety meloxicam is approximately 20 hours (range 12-24 h), allowing once-daily dosing in chronic pain.
Approximately 50% of a dose is eliminated via first-pass hepatic metabolism; renal excretion accounts for ~65% of the administered dose as metabolites (<1% unchanged drug); fecal excretion <20%.
VIVLODEX is a meloxicam NSAID prodrug. Following hydrolysis to meloxicam, excretion is primarily hepatic (metabolism) and renal (urine). Approximately 50% of meloxicam dose is excreted in urine as metabolites and <5% as parent drug; about 40% in feces. Biliary excretion is minor.
Category D/X
Category C
NSAID
NSAID